GSK plc’s GSK Specialty Medicines segment includes medicines that prevent and treat diseases like HIV, cancer, asthma and immune-inflammation diseases like lupus. Specialty Medicines now represents ...

The UK's FTSE 100 surpassed the 9,000-point mark for the first time on Tuesday, as investors took comfort in a relatively ...

Irish Ferries brand owner Irish Continental Group was the strongest performer on the index, closing up 1.44 per cent to €5.64 ...

GSK has been enjoying regulatory momentum in recent months as it works to bring its antibody-drug conjugate (ADC) Blenrep ...

GSK (GSK) stock in focus as the company secures EU approval for Blenrep combo therapies targeting the blood cancer multiple ...

The FDA’s Oncologic Drugs Advisory Committee has voted against the benefit/risk profile of GSK’s Blenrep just days before the drug’s PDUFA date.

The U.S. FDA’s Oncologic Drugs Advisory Committee took up the matter of GSK plc’s relapsed/refractory multiple myeloma drug, Blenrep (belantamab mafodotin). A B-cell maturation antigen-directed ...

GSK specialty medicines grew YoY in Q1 2025, and it is now the main profit engine, offsetting the weakness in their vaccine segment. See why the stock is a Buy.

The growth impact may be compounded over time as slower population growth—or shrinking populations—leads to fewer new ideas and inventions that power long-term productivity growth. Second, people’s ...

Senator Maggie Hassan is investigating GSK's discontinuation of Flovent HFA, citing increased hospitalizations, higher drug costs, and lost Medicaid rebates.

MorganFranklin Cyber announces promotion of two longtime leaders to newly created roles designed to support strategic growth & client-centric mission.

U.S. Senator Maggie Hassan said on Friday she is launching an investigation into British pharmaceutical giant GlaxoSmithKline's decision to discontinue a widely used asthma inhaler for children.